118 related articles for article (PubMed ID: 38030185)
1. Association Between High Expression of Phosphorylated-STMN1 and Mesenchymal Marker Expression and Cancer Stemness in Breast Cancer.
Handa T; Yokobori T; Obayashi S; Fujii T; Shirabe K; Oyama T
Anticancer Res; 2023 Dec; 43(12):5341-5348. PubMed ID: 38030185
[TBL] [Abstract][Full Text] [Related]
2. The prognostic role of a phospho-Stathmin 1 signature in breast cancer treated with neoadjuvant chemotherapy.
Xie Z; Zhen T; Lin Y; Shao N; Kuang X
Gland Surg; 2022 Nov; 11(11):1808-1816. PubMed ID: 36518803
[TBL] [Abstract][Full Text] [Related]
3. Stathmin1 expression is associated with aggressive phenotypes and cancer stem cell marker expression in breast cancer patients.
Obayashi S; Horiguchi J; Higuchi T; Katayama A; Handa T; Altan B; Bai T; Bao P; Bao H; Yokobori T; Nishiyama M; Oyama T; Kuwano H
Int J Oncol; 2017 Sep; 51(3):781-790. PubMed ID: 28766688
[TBL] [Abstract][Full Text] [Related]
4. The phosphorylation-specific association of STMN1 with GRP78 promotes breast cancer metastasis.
Kuang XY; Jiang HS; Li K; Zheng YZ; Liu YR; Qiao F; Li S; Hu X; Shao ZM
Cancer Lett; 2016 Jul; 377(1):87-96. PubMed ID: 27130664
[TBL] [Abstract][Full Text] [Related]
5. Stathmin and phospho-stathmin protein signature is associated with survival outcomes of breast cancer patients.
Kuang XY; Chen L; Zhang ZJ; Liu YR; Zheng YZ; Ling H; Qiao F; Li S; Hu X; Shao ZM
Oncotarget; 2015 Sep; 6(26):22227-38. PubMed ID: 26087399
[TBL] [Abstract][Full Text] [Related]
6. Expression of epithelial-mesenchymal transition-related markers in triple-negative breast cancer: ZEB1 as a potential biomarker for poor clinical outcome.
Jang MH; Kim HJ; Kim EJ; Chung YR; Park SY
Hum Pathol; 2015 Sep; 46(9):1267-74. PubMed ID: 26170011
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of Stathmin1 expression and epithelial-mesenchymal transition in curatively resected gastric cancer.
Ke B; Guo XF; Li N; Wu LL; Li B; Zhang RP; Liang H
Mol Clin Oncol; 2019 Feb; 10(2):214-222. PubMed ID: 30680197
[TBL] [Abstract][Full Text] [Related]
8. G2/M transition requires multisite phosphorylation of oncoprotein 18 by two distinct protein kinase systems.
Larsson N; Melander H; Marklund U; Osterman O; Gullberg M
J Biol Chem; 1995 Jun; 270(23):14175-83. PubMed ID: 7775478
[TBL] [Abstract][Full Text] [Related]
9. Protein Phosphatase 1 Subunit PPP1R14B Stabilizes STMN1 to Promote Progression and Paclitaxel Resistance in Triple-Negative Breast Cancer.
Liao L; Zhang YL; Deng L; Chen C; Ma XY; Andriani L; Yang SY; Hu SY; Zhang FL; Shao ZM; Li DQ
Cancer Res; 2023 Feb; 83(3):471-484. PubMed ID: 36484700
[TBL] [Abstract][Full Text] [Related]
10. Cell-cycle-regulated phosphorylation of oncoprotein 18 on Ser16, Ser25 and Ser38.
Brattsand G; Marklund U; Nylander K; Roos G; Gullberg M
Eur J Biochem; 1994 Mar; 220(2):359-68. PubMed ID: 8125092
[TBL] [Abstract][Full Text] [Related]
11. GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer.
Vijay GV; Zhao N; Den Hollander P; Toneff MJ; Joseph R; Pietila M; Taube JH; Sarkar TR; Ramirez-Pena E; Werden SJ; Shariati M; Gao R; Sobieski M; Stephan CC; Sphyris N; Miura N; Davies P; Chang JT; Soundararajan R; Rosen JM; Mani SA
Breast Cancer Res; 2019 Mar; 21(1):37. PubMed ID: 30845991
[TBL] [Abstract][Full Text] [Related]
12. STMN1 Promotes Tumor Metastasis in Non-small Cell Lung Cancer Through Microtubule-dependent And Nonmicrotubule-dependent Pathways.
Zeng L; Lyu X; Yuan J; Chen Y; Wen H; Zhang L; Shi J; Liu B; Li W; Yang S
Int J Biol Sci; 2024; 20(4):1509-1527. PubMed ID: 38385074
[TBL] [Abstract][Full Text] [Related]
13. An Immunohistochemical Study of Stathmin 1 Expression in Osteosarcoma Shows an Association with Metastases and Poor Patient Prognosis.
Zhao C; Li H; Wang L; Sun W
Med Sci Monit; 2018 Aug; 24():6070-6078. PubMed ID: 30169496
[TBL] [Abstract][Full Text] [Related]
14. Stathmin1 overexpression in hypopharyngeal squamous cell carcinoma: A new promoter in FaDu cell proliferation and migration.
Chen Y; Zhang Q; Ding C; Zhang X; Qiu X; Zhang Z
Int J Oncol; 2017 Jan; 50(1):31-40. PubMed ID: 27878293
[TBL] [Abstract][Full Text] [Related]
15. MAGE-A is frequently expressed in triple negative breast cancer and associated with epithelial-mesenchymal transition.
Wang H; Sang M; Geng C; Liu F; Gu L; Shan B
Neoplasma; 2016; 63(1):44-56. PubMed ID: 26639233
[TBL] [Abstract][Full Text] [Related]
16. Embryonic stem cell secreted factors decrease invasiveness of triple-negative breast cancer cells through regulome modulation.
Tarasewicz E; Oakes RS; Aviles MO; Straehla J; Chilton KM; Decker JT; Wu J; Shea LD; Jeruss JS
Cancer Biol Ther; 2018 Apr; 19(4):271-281. PubMed ID: 29053396
[TBL] [Abstract][Full Text] [Related]
17. MiR-101 is involved in human breast carcinogenesis by targeting Stathmin1.
Wang R; Wang HB; Hao CJ; Cui Y; Han XC; Hu Y; Li FF; Xia HF; Ma X
PLoS One; 2012; 7(10):e46173. PubMed ID: 23071542
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of Stathmin 1 correlates with poor prognosis and promotes cell migration and proliferation in oesophageal squamous cell carcinoma.
Ni PZ; He JZ; Wu ZY; Ji X; Chen LQ; Xu XE; Liao LD; Wu JY; Li EM; Xu LY
Oncol Rep; 2017 Dec; 38(6):3608-3618. PubMed ID: 29039594
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of stathmin 1 is a poor prognostic biomarker in non-small cell lung cancer.
Nie W; Xu MD; Gan L; Huang H; Xiu Q; Li B
Lab Invest; 2015 Jan; 95(1):56-64. PubMed ID: 25384122
[TBL] [Abstract][Full Text] [Related]
20. Stathmin1 regulates p27 expression, proliferation and drug resistance, resulting in poor clinical prognosis in cholangiocarcinoma.
Watanabe A; Suzuki H; Yokobori T; Tsukagoshi M; Altan B; Kubo N; Suzuki S; Araki K; Wada S; Kashiwabara K; Hosouchi Y; Kuwano H
Cancer Sci; 2014 Jun; 105(6):690-6. PubMed ID: 24708177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
